Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations analyze identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CX